Skip to main content
Top
Published in: Journal of Neuroinflammation 1/2010

Open Access 01-12-2010 | Research

Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death

Authors: Noel G Carlson, Monica A Rojas, Jonathan W Redd, Philip Tang, Blair Wood, Kenneth E Hill, John W Rose

Published in: Journal of Neuroinflammation | Issue 1/2010

Login to get access

Abstract

Background

We previously found that cyclooxygenase 2 (COX-2) was expressed in dying oligodendrocytes at the onset of demyelination in the Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) model of multiple sclerosis (MS) (Carlson et al. J.Neuroimmunology 2006, 149:40). This suggests that COX-2 may contribute to death of oligodendrocytes.

Objective

The goal of this study was to examine whether COX-2 contributes to excitotoxic death of oligodendrocytes and potentially contributes to demyelination.

Methods

The potential link between COX-2 and oligodendrocyte death was approached using histopathology of MS lesions to examine whether COX-2 was expressed in dying oligodendrocytes. COX-2 inhibitors were examined for their ability to limit demyelination in the TMEV-IDD model of MS and to limit excitotoxic death of oligodendrocytes in vitro. Genetic manipulation of COX-2 expression was used to determine whether COX-2 contributes to excitotoxic death of oligodendrocytes. A transgenic mouse line was generated that overexpressed COX-2 in oligodendrocytes. Oligodendrocyte cultures derived from these transgenic mice were used to examine whether increased expression of COX-2 enhanced the vulnerability of oligodendrocytes to excitotoxic death. Oligodendrocytes derived from COX-2 knockout mice were evaluated to determine if decreased COX-2 expression promotes a greater resistance to excitotoxic death.

Results

COX-2 was expressed in dying oligodendrocytes in MS lesions. COX-2 inhibitors limited demyelination in the TMEV-IDD model of MS and protected oligodendrocytes against excitotoxic death in vitro. COX-2 expression was increased in wild-type oligodendrocytes following treatment with Kainic acid (KA). Overexpression of COX-2 in oligodendrocytes increased the sensitivity of oligodendrocytes to KA-induced excitotoxic death eight-fold compared to wild-type. Conversely, oligodendrocytes prepared from COX-2 knockout mice showed a significant decrease in sensitivity to KA induced death.

Conclusions

COX-2 expression was associated with dying oligodendrocytes in MS lesions and appeared to increase excitotoxic death of oligodendrocytes in culture. An understanding of how COX-2 expression influences oligodendrocyte death leading to demyelination may have important ramifications for future treatments for MS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med. 2000, 343: 938-952. 10.1056/NEJM200009283431307.CrossRefPubMed Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med. 2000, 343: 938-952. 10.1056/NEJM200009283431307.CrossRefPubMed
2.
go back to reference Weinshenker BG, Ebers GC: The natural history of multiple sclerosis. Can J Neurol Sci. 1987, 14: 255-261.PubMed Weinshenker BG, Ebers GC: The natural history of multiple sclerosis. Can J Neurol Sci. 1987, 14: 255-261.PubMed
3.
go back to reference Frohman EM, Racke MK, Raine CS: Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006, 354: 942-955. 10.1056/NEJMra052130.CrossRefPubMed Frohman EM, Racke MK, Raine CS: Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006, 354: 942-955. 10.1056/NEJMra052130.CrossRefPubMed
4.
go back to reference Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol. 2005, 23: 683-747. 10.1146/annurev.immunol.23.021704.115707.CrossRefPubMed Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol. 2005, 23: 683-747. 10.1146/annurev.immunol.23.021704.115707.CrossRefPubMed
5.
go back to reference Lipton HL: Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun. 1975, 115: 1147-55. Lipton HL: Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun. 1975, 115: 1147-55.
6.
go back to reference Tsunoda I, Fujinami RS: Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J Neuropathol Exp Neurol. 1996, 55: 673-686. 10.1097/00005072-199606000-00001.CrossRefPubMed Tsunoda I, Fujinami RS: Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J Neuropathol Exp Neurol. 1996, 55: 673-686. 10.1097/00005072-199606000-00001.CrossRefPubMed
7.
go back to reference Werner P, Pitt D, Raine CS: Glutamate excitotoxicity--a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?. J Neural Transm Suppl. 2000, 60: 375-385.PubMed Werner P, Pitt D, Raine CS: Glutamate excitotoxicity--a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?. J Neural Transm Suppl. 2000, 60: 375-385.PubMed
8.
go back to reference Smith T, Groom A, Zhu B, Turski L: Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med. 2000, 6: 62-66. 10.1038/71548.CrossRefPubMed Smith T, Groom A, Zhu B, Turski L: Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med. 2000, 6: 62-66. 10.1038/71548.CrossRefPubMed
9.
go back to reference Pitt D, Werner P, Raine CS: Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 2000, 6: 67-70. 10.1038/71555.CrossRefPubMed Pitt D, Werner P, Raine CS: Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 2000, 6: 67-70. 10.1038/71555.CrossRefPubMed
10.
go back to reference Verkhratsky A, Steinhauser C: Ion channels in glial cells. Brain Res Rev. 2000, 322: 380-412. 10.1016/S0165-0173(99)00093-4.CrossRef Verkhratsky A, Steinhauser C: Ion channels in glial cells. Brain Res Rev. 2000, 322: 380-412. 10.1016/S0165-0173(99)00093-4.CrossRef
11.
go back to reference Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV: The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 2001, 24: 224-230. 10.1016/S0166-2236(00)01746-X.CrossRefPubMed Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV: The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 2001, 24: 224-230. 10.1016/S0166-2236(00)01746-X.CrossRefPubMed
12.
go back to reference Smith WL, DeWitt DL: Prostaglandin endoperoxide H synthases cyclooxygenases-1 and -2. Adv Immunol. 1996, 62: 167-215. full_text.CrossRefPubMed Smith WL, DeWitt DL: Prostaglandin endoperoxide H synthases cyclooxygenases-1 and -2. Adv Immunol. 1996, 62: 167-215. full_text.CrossRefPubMed
13.
go back to reference Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000, 293: 417-425.PubMed Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000, 293: 417-425.PubMed
14.
go back to reference Carlson NG: Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res. 2003, 71: 79-88. 10.1002/jnr.10465.CrossRefPubMed Carlson NG: Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res. 2003, 71: 79-88. 10.1002/jnr.10465.CrossRefPubMed
15.
go back to reference Nogawa S, Zhang F, Ross ME, Iadecola C: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. 1997, 17: 2746-2755.PubMed Nogawa S, Zhang F, Ross ME, Iadecola C: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. 1997, 17: 2746-2755.PubMed
16.
go back to reference Nagayama M, Niwa K, Nagayama T, Ross ME, Iadecola C: The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab. 1999, 19: 1213-1219. 10.1097/00004647-199911000-00005.CrossRefPubMed Nagayama M, Niwa K, Nagayama T, Ross ME, Iadecola C: The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab. 1999, 19: 1213-1219. 10.1097/00004647-199911000-00005.CrossRefPubMed
17.
go back to reference Kelley KA, Ho L, Winger D, Freire-Moar J, Borelli CB, Aisen PS, Pasinetti GM: Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999, 155: 995-1004.PubMedCentralCrossRefPubMed Kelley KA, Ho L, Winger D, Freire-Moar J, Borelli CB, Aisen PS, Pasinetti GM: Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999, 155: 995-1004.PubMedCentralCrossRefPubMed
18.
go back to reference Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, Shang Y, Shaffer A, Kaufmann WE, Worley PF, Isakson P, Markowska AL: Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci. 2001, 21: 8198-8209.PubMed Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, Shang Y, Shaffer A, Kaufmann WE, Worley PF, Isakson P, Markowska AL: Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci. 2001, 21: 8198-8209.PubMed
19.
go back to reference Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME: Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA. 2001, 98: 1294-1299. 10.1073/pnas.98.3.1294.PubMedCentralCrossRefPubMed Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME: Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA. 2001, 98: 1294-1299. 10.1073/pnas.98.3.1294.PubMedCentralCrossRefPubMed
20.
go back to reference Rose JW, Hill KE, Watt HE, Carlson NG: Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J Neuroimmunol. 2004, 149: 40-49. 10.1016/j.jneuroim.2003.12.021.CrossRefPubMed Rose JW, Hill KE, Watt HE, Carlson NG: Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J Neuroimmunol. 2004, 149: 40-49. 10.1016/j.jneuroim.2003.12.021.CrossRefPubMed
21.
go back to reference Carlson NG, Hill KE, Tsunoda I, Fujinami RS, Rose JW: The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J Neuroimmunol. 2006, 174: 21-31. 10.1016/j.jneuroim.2006.01.008.CrossRefPubMed Carlson NG, Hill KE, Tsunoda I, Fujinami RS, Rose JW: The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J Neuroimmunol. 2006, 174: 21-31. 10.1016/j.jneuroim.2006.01.008.CrossRefPubMed
22.
go back to reference Tsoi VL, Hill KE, Carlson NG, Warner JE, Rose JW: Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol. 2006, 262: 87-94.CrossRef Tsoi VL, Hill KE, Carlson NG, Warner JE, Rose JW: Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol. 2006, 262: 87-94.CrossRef
23.
go back to reference Bruce-Keller AJ, Geddes JW, Knapp PE, McFall RW, Keller JN, Holtsberg FW, Parthasarathy S, Steiner SM, Mattson MP: Anti-death properties of TNF against metabolic poisoning: mitochondrial stabilization by MnSOD. J Neuroimmunol. 1999, 93: 53-71. 10.1016/S0165-5728(98)00190-8.CrossRefPubMed Bruce-Keller AJ, Geddes JW, Knapp PE, McFall RW, Keller JN, Holtsberg FW, Parthasarathy S, Steiner SM, Mattson MP: Anti-death properties of TNF against metabolic poisoning: mitochondrial stabilization by MnSOD. J Neuroimmunol. 1999, 93: 53-71. 10.1016/S0165-5728(98)00190-8.CrossRefPubMed
24.
go back to reference Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC: Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol. 1999, 163: 3963-3968.PubMed Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC: Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol. 1999, 163: 3963-3968.PubMed
25.
go back to reference Carlson NG, Rojas MA, Black JD, Redd JW, Hille J, Hill KE, Rose JW: Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation. 2009, 6: 5-10.1186/1742-2094-6-5.PubMedCentralCrossRefPubMed Carlson NG, Rojas MA, Black JD, Redd JW, Hille J, Hill KE, Rose JW: Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation. 2009, 6: 5-10.1186/1742-2094-6-5.PubMedCentralCrossRefPubMed
26.
go back to reference Drachman DB, Frank BS, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, Rothstein JD: Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic model of ALS. Ann Neurol. 2002, 52: 771-778. 10.1002/ana.10374.CrossRefPubMed Drachman DB, Frank BS, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, Rothstein JD: Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic model of ALS. Ann Neurol. 2002, 52: 771-778. 10.1002/ana.10374.CrossRefPubMed
27.
go back to reference Chandross KJ, Cohen RI, Paras P, Gravel M, Braun PE, Hudson LD: Identification and characterization of early glial progenitors using a transgenic selection strategy. J Neurosci. 1999, 192: 759-774. Chandross KJ, Cohen RI, Paras P, Gravel M, Braun PE, Hudson LD: Identification and characterization of early glial progenitors using a transgenic selection strategy. J Neurosci. 1999, 192: 759-774.
28.
go back to reference Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM, Goulet JL, Smithies O, Koller BH, Langenbach R: Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA. 2001, 98: 1059-1064. 10.1073/pnas.031573498.PubMedCentralCrossRefPubMed Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM, Goulet JL, Smithies O, Koller BH, Langenbach R: Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA. 2001, 98: 1059-1064. 10.1073/pnas.031573498.PubMedCentralCrossRefPubMed
29.
go back to reference Sanchez-Gomez MV, Alberdi E, Ibarretxe G, Torre I, Matute C: Caspase-dependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci. 2003, 232: 9519-9528. Sanchez-Gomez MV, Alberdi E, Ibarretxe G, Torre I, Matute C: Caspase-dependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci. 2003, 232: 9519-9528.
30.
go back to reference Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001, 15: 2057-2072. 10.1096/fj.01-0390rev.CrossRefPubMed Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001, 15: 2057-2072. 10.1096/fj.01-0390rev.CrossRefPubMed
31.
go back to reference Balabanov R, Popko B: Myelin repair: developmental myelination redux?. Nature Neurosci. 2005, 8: 262-265. 10.1038/nn0305-262.CrossRefPubMed Balabanov R, Popko B: Myelin repair: developmental myelination redux?. Nature Neurosci. 2005, 8: 262-265. 10.1038/nn0305-262.CrossRefPubMed
32.
go back to reference Arnett HA, Fancy SP, Alberta JA, Zhao C, Plant SR, Kaing S, Raine CS, Rowitch DH, Franklin RJM, Stiles CD: BHLH transcription factor olig1 is required to repair demyelinated lesions in the CNS. Science. 2004, 306: 2111-2115. 10.1126/science.1103709.CrossRefPubMed Arnett HA, Fancy SP, Alberta JA, Zhao C, Plant SR, Kaing S, Raine CS, Rowitch DH, Franklin RJM, Stiles CD: BHLH transcription factor olig1 is required to repair demyelinated lesions in the CNS. Science. 2004, 306: 2111-2115. 10.1126/science.1103709.CrossRefPubMed
33.
go back to reference Leuschen MP, Filipi M, Healey K: A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Mult Scler. 2004, 10: 636-642. 10.1191/1352458504ms1114oa.CrossRefPubMed Leuschen MP, Filipi M, Healey K: A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Mult Scler. 2004, 10: 636-642. 10.1191/1352458504ms1114oa.CrossRefPubMed
34.
go back to reference Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M: A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005, 64: 1267-1269.CrossRefPubMed Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M: A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005, 64: 1267-1269.CrossRefPubMed
35.
go back to reference Wingerchuk DM, Rodriguez M: Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin. Arch Neurol. 2006, 63: 1005-1008. 10.1001/archneur.63.7.1005.CrossRefPubMed Wingerchuk DM, Rodriguez M: Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin. Arch Neurol. 2006, 63: 1005-1008. 10.1001/archneur.63.7.1005.CrossRefPubMed
36.
go back to reference Muthian G, Raikwar HP, Johnson C, Rajasingh J, Kalgutkar A, Marnett LJ, Bright JJ: COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol. 2006, 261: 73-85. 10.1007/s10875-006-8787-y.CrossRef Muthian G, Raikwar HP, Johnson C, Rajasingh J, Kalgutkar A, Marnett LJ, Bright JJ: COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol. 2006, 261: 73-85. 10.1007/s10875-006-8787-y.CrossRef
37.
go back to reference Miyamoto K, Miyake S, Mizuno M, Oka N, Kusunoki S, Yamamura T: Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain. 2006, 129: 1984-1992. 10.1093/brain/awl170.CrossRefPubMed Miyamoto K, Miyake S, Mizuno M, Oka N, Kusunoki S, Yamamura T: Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain. 2006, 129: 1984-1992. 10.1093/brain/awl170.CrossRefPubMed
38.
go back to reference Reder AT, Thapar M, Supugay AM, Jensen MA: Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol. 1994, 54: 117-127. 10.1016/0165-5728(94)90238-0.CrossRefPubMed Reder AT, Thapar M, Supugay AM, Jensen MA: Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol. 1994, 54: 117-127. 10.1016/0165-5728(94)90238-0.CrossRefPubMed
39.
go back to reference Reder AT, Thapar M, Supugay AM, Jensen MA: Eicosenoids modify experimental allergic encephalomyelitis. Am J Ther. 1995, 2: 711-720. 10.1097/00045391-199509000-00020.CrossRefPubMed Reder AT, Thapar M, Supugay AM, Jensen MA: Eicosenoids modify experimental allergic encephalomyelitis. Am J Ther. 1995, 2: 711-720. 10.1097/00045391-199509000-00020.CrossRefPubMed
40.
go back to reference Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira J, Ishii S, Shimizu T: Targeted lidpdomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proceedings Nat Acad Sci USA. 2009, 106: 21807-21812. 10.1073/pnas.0906891106.CrossRef Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira J, Ishii S, Shimizu T: Targeted lidpdomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proceedings Nat Acad Sci USA. 2009, 106: 21807-21812. 10.1073/pnas.0906891106.CrossRef
41.
go back to reference Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW: Inducible nitric oxide synthase in multiple sclerosis plaques: distribution, cellular expression, and pathologic consequences. J Neuroimmunol. 2004, 151: 171-179. 10.1016/j.jneuroim.2004.02.005.CrossRefPubMed Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW: Inducible nitric oxide synthase in multiple sclerosis plaques: distribution, cellular expression, and pathologic consequences. J Neuroimmunol. 2004, 151: 171-179. 10.1016/j.jneuroim.2004.02.005.CrossRefPubMed
42.
go back to reference Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP: Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol. 1998, 88: 45-56. 10.1016/S0165-5728(98)00078-2.CrossRefPubMed Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP: Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol. 1998, 88: 45-56. 10.1016/S0165-5728(98)00078-2.CrossRefPubMed
43.
go back to reference Liu JS, Zhao ML, Brosnan CF, Lee SC: Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol. 2001, 158: 2057-2066.PubMedCentralCrossRefPubMed Liu JS, Zhao ML, Brosnan CF, Lee SC: Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol. 2001, 158: 2057-2066.PubMedCentralCrossRefPubMed
44.
go back to reference Coleman RA, Smith WL, Narumiya S: International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994, 46: 205-229.PubMed Coleman RA, Smith WL, Narumiya S: International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994, 46: 205-229.PubMed
45.
go back to reference Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C: Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol. 2004, 55: 668-675. 10.1002/ana.20078.CrossRefPubMed Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C: Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol. 2004, 55: 668-675. 10.1002/ana.20078.CrossRefPubMed
46.
go back to reference Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C: Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med. 2006, 12: 225-229. 10.1038/nm1362.CrossRefPubMed Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C: Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med. 2006, 12: 225-229. 10.1038/nm1362.CrossRefPubMed
47.
go back to reference Ahmad AS, Saleem S, Ahmad M, Dore S: Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci. 2006, 89: 265-270. 10.1093/toxsci/kfj022.CrossRefPubMed Ahmad AS, Saleem S, Ahmad M, Dore S: Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci. 2006, 89: 265-270. 10.1093/toxsci/kfj022.CrossRefPubMed
48.
go back to reference Gendron TF, Brunette E, Tauskela JS, Morley P: The dual role of prostaglandin E2 in excitotoxicity and preconditioning-induced neuroprotection. Eur J Pharm. 2005, 517: 12-27.CrossRef Gendron TF, Brunette E, Tauskela JS, Morley P: The dual role of prostaglandin E2 in excitotoxicity and preconditioning-induced neuroprotection. Eur J Pharm. 2005, 517: 12-27.CrossRef
49.
go back to reference Dore S: GPCR antagonists as an alternative to COX-2 inhibitors: a case for PGE2 EP1 receptor. TRENDS in Pharm Sci. 2006, 27: 458-460. 10.1016/j.tips.2006.07.001.CrossRef Dore S: GPCR antagonists as an alternative to COX-2 inhibitors: a case for PGE2 EP1 receptor. TRENDS in Pharm Sci. 2006, 27: 458-460. 10.1016/j.tips.2006.07.001.CrossRef
50.
go back to reference Zhou P, Qian L, Chou T, Iadecola C: Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis. 2008, 29: 543-551. 10.1016/j.nbd.2007.11.010.PubMedCentralCrossRefPubMed Zhou P, Qian L, Chou T, Iadecola C: Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis. 2008, 29: 543-551. 10.1016/j.nbd.2007.11.010.PubMedCentralCrossRefPubMed
51.
go back to reference McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K: Neuroprotective function of PGE2 EP2 receptor in cerebral ischemia. J Neurosci. 2004, 24: 257-268. 10.1523/JNEUROSCI.4485-03.2004.CrossRefPubMed McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K: Neuroprotective function of PGE2 EP2 receptor in cerebral ischemia. J Neurosci. 2004, 24: 257-268. 10.1523/JNEUROSCI.4485-03.2004.CrossRefPubMed
52.
go back to reference Ahmad AS, Zhuang H, Echeveriia V, Dore S: Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma. 2006, 23: 1895-1903. 10.1089/neu.2006.23.1895.CrossRefPubMed Ahmad AS, Zhuang H, Echeveriia V, Dore S: Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma. 2006, 23: 1895-1903. 10.1089/neu.2006.23.1895.CrossRefPubMed
53.
go back to reference Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Dore S: Prostagland EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 2005, 1066: 71-77. 10.1016/j.brainres.2005.10.068.CrossRefPubMed Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Dore S: Prostagland EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 2005, 1066: 71-77. 10.1016/j.brainres.2005.10.068.CrossRefPubMed
54.
go back to reference Xiang Z, Lin T, Reeves SA: 15d-PGJ2 induces apoptosis of mouse oligodendrocyte precursor cells. J Neuroinflammation. 2007, 4: 18-10.1186/1742-2094-4-18.PubMedCentralCrossRefPubMed Xiang Z, Lin T, Reeves SA: 15d-PGJ2 induces apoptosis of mouse oligodendrocyte precursor cells. J Neuroinflammation. 2007, 4: 18-10.1186/1742-2094-4-18.PubMedCentralCrossRefPubMed
55.
go back to reference Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med. 2004, 351: 1709-1711. 10.1056/NEJMp048288.CrossRefPubMed Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med. 2004, 351: 1709-1711. 10.1056/NEJMp048288.CrossRefPubMed
56.
go back to reference Topol EJ: Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med. 2004, 351: 1707-1709. 10.1056/NEJMp048286.CrossRefPubMed Topol EJ: Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med. 2004, 351: 1707-1709. 10.1056/NEJMp048286.CrossRefPubMed
Metadata
Title
Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death
Authors
Noel G Carlson
Monica A Rojas
Jonathan W Redd
Philip Tang
Blair Wood
Kenneth E Hill
John W Rose
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2010
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-7-25

Other articles of this Issue 1/2010

Journal of Neuroinflammation 1/2010 Go to the issue